Multiple inflammatory mechanisms in eosinophilic oesophagitis make it unlikely that single pathway inhibition by monoclonal biological therapies would succeed
- PMID: 37640444
- DOI: 10.1136/gutjnl-2023-330590
Multiple inflammatory mechanisms in eosinophilic oesophagitis make it unlikely that single pathway inhibition by monoclonal biological therapies would succeed
Keywords: DRUG DEVELOPMENT; INFLAMMATORY MECHANISMS; OESOPHAGEAL DISORDERS; PHARMACOTHERAPY.
Conflict of interest statement
Competing interests: The author has received payments for work as an advisory consultant or speaker for AstraZeneca, BristolMyersSquib, Dr Falk Pharma, GlaxoSmithKline and Regeneron Sanofi.
Comment on
-
Mepolizumab for treatment of adolescents and adults with eosinophilic oesophagitis: a multicentre, randomised, double-blind, placebo-controlled clinical trial.Gut. 2023 Oct;72(10):1828-1837. doi: 10.1136/gutjnl-2023-330337. Epub 2023 Jul 9. Gut. 2023. PMID: 37423717 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical